Allergan, Inc.

Other

Allergen, Inc.

David W Old

Robert M Burk

Danny Thang Dinh

Vinh X Ngo

Todd S Gac

Thang D Dinh

Yariv Donde

Mark Holoboski

Wha Bin Im

Mari F Posner

Christopher D Hein

Michael E Garst

Wha-Bin Im

Brent A Johnson

John E Donello

David Frederick Woodward

Daniel W Gil

Larry Allen Wheeler

Tien T Duong

Veena Viswanath

Santosh C Sinha

Ling Li

Richard S Graham

Jeremiah H Nguyen

June Chen

Yanbin Liang

Sandhya Rao

Karen M Kedzie

Achim H-p Krauss

Elizabeth T Syage

Mu-Lan Lee

Boris Gorin

Christopher M Lanthier

Jan Oudenes

Boris I Gorin

Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:  The compounds are useful for treating inflammatory and autoimmune diseases.

3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof

Described herein are compounds that are EPagonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EPreceptors.

EPagonists as therapeutic compounds

Disclosed herein are compounds according to Formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (IOP) or causing hair growth, and methods of using the same. 

Quaternary ammonium alkyl esters as stable prodrugs

EP4 agonists as therapeutic compounds

Disclosed herein are compounds having formula (I) wherein a dashed line represents the presence or adsence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ester thereof; or Y is a tetrazolyl functional group; A is &#x2014;(CH)&#x2014;, cis &#x2014;CHCH&#x2550;CH&#x2014;(CH)&#x2014;, or &#x2014;CHC&#x2550;C&#x2014;(CH)&#x2014;, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is &#x2014;(CH)&#x2014;Ar&#x2014;(CH)&#x2014;, wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 &#x2014;CH&#x2014; may be replaced by S or O, and 1 &#x2014;CH&#x2014;CH&#x2014; may be replaced by &#x2014;CH&#x2550;CH&#x2014; or &#x2014;C&#x2261;C&#x2014;; Uand Uare independently selected from &#x2014;H, &#x2550;O, &#x2014;OH, &#x2014;F, &#x2014;Cl, and &#x2014;CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.

Therapeutic substituted cyclopentanes

This invention provides well defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds for treating glaucoma or ocular hypertension.

Therapeutic agents for ocular hypertension

Disclosed herein are compounds of the formula: compositions thereof, and methods for the treatment of glaucoma, reducing intraocular pressure, and other prostaglandin EPmediated disease and disorders.

Therapeutic substituted pyrroles

Disclosed herein are compounds having the formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ether thereof; or Y is a tetrazolyl functional group; A is &#x2014;(CH)&#x2014;, cis &#x2014;CHCH&#x2550;CH&#x2014;(CH)&#x2014;, or &#x2014;CHC&#x2550;C&#x2014;(CH)&#x2014;, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is &#x2014;(CH)&#x2014;Ar&#x2014;(CH)&#x2014; wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 &#x2014;CH&#x2014; may be replaced by S or O, and 1 &#x2014;CH&#x2014;CH&#x2014; may be replaced by &#x2014;CH&#x2550;CH&#x2014; or &#x2014;C&#x2261;C&#x2014;; Uand Uare independently selected from &#x2014;H, &#x2550;O, &#x2014;OH, &#x2014;F, &#x2014;Cl, and &#x2014;CN; and B is aryl or heteroaryl, for use as acular hypotensive agent. 

The invention provides compositions and methods for reducing healing wounds and reducing scars and blemishes. The compositions and methods of the invention include at least one EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such as surgery, trauma, disease, mechanical injury, burn, radiation, poisoning, and the like.

15-aryl prostaglandins as EP4 agonists, and methods of use thereof

The invention provides well-defined compounds that are either EPagonists, EPagonists, or mixed EP/EPagonist. The compounds are useful for treating a variety of pathological conditions associated with activity of the EPand/or EPreceptors.

Therapeutic agents

Compounds such as those represented by Formulas 1-6 can be used in topical liquids, creams, or other dosage forms such as solids, for reducing intraocular pressure, treating glaucoma, growing hair, or other medical uses.

Secondary amines as therapeutic agents

The invention provides well-defined amides for treating glaucoma and ocular hypertension.

Therapeutic agents for treatment of ocular hypertension

The present invention provides synthetic processes for the preparation of a variety of well-defined substituted gamma lactams. The compounds that can be prepared by the process of the invention are useful for treating a variety of conditions. In some embodiments of the invention, the compounds are useful for treating ocular disorders, such as, for example, glaucoma, lowering of elevated intraocular pressure, and the like. In other embodiments, the compounds are useful for treating irritable bowel disease. In further embodiments, the compounds are useful in promoting hair growth. In still further embodiments, the compounds are useful in promoting wound healing, scar reduction, and the like.

Process for the synthesis of substituted gamma lactams

Disclosed herein is a compound having a structure Therapeutic methods, compositions, and medicaments related thereto are also disclosed.

Growing community of inventors

Irvine, CA, United States of America

David W Old